8. Other TherapiesStrontium ranelat

8. Other Therapies
Strontium ranelate is an oral agent possessing bone-forming and antiresorptive properties. Some data suggest significant reductions in vertebral fractures. However, the benefit in nonvertebral fractures is unclear. This agent has not yet been approved for use by the FDA. Sodium fluoride is an agent with bone-forming properties. Its use has fallen out of favor after data suggested an increased risk of fracture despite increases in bone mineral density. It is not currently available commercially in the United States. Thiazide diuretics decrease urinary calcium excretion and may decrease bone turnover. However, their effects on bone mineral density and fracture rates have not been studied in controlled trials. Thiazide diuretics are not recommended solely for potential beneficial effects in osteoporosis. Interest in the role of HMG-CoA reductase inhibitors (statins) in the treatment of osteoporosis came from boneforming properties seen in animal studies. However, controlled clinical trials are needed. Several studies have evaluated dietary supplements such as isoflavones, which are found in soy products and red clover. A well-controlled trial in more than 400 postmenopausal women evaluating a specific isoflavone, ipriflavone, found no benefits on bone mineral density or fracture rates after 3 years. Nevertheless, because these therapies are available without prescription and are not regulated by the FDA, patients may choose to self-medicate with isoflavones. Lymphocytopenia appeared in several patients treated with ipriflavone in clinical trials. Additionally, ipriflavone should be used with caution in immunocompromised patients or those with renal disease. It may inhibit CYP1A2 and CYP2C9 and may interact with drugs metabolized by those pathways, such as warfarin.

Results (Indonesian) 1:

8. terapi lainStrontium ranelate is an oral agent possessing bone-forming and antiresorptive properties. Some data suggest significant reductions in vertebral fractures. However, the benefit in nonvertebral fractures is unclear. This agent has not yet been approved for use by the FDA. Sodium fluoride is an agent with bone-forming properties. Its use has fallen out of favor after data suggested an increased risk of fracture despite increases in bone mineral density. It is not currently available commercially in the United States. Thiazide diuretics decrease urinary calcium excretion and may decrease bone turnover. However, their effects on bone mineral density and fracture rates have not been studied in controlled trials. Thiazide diuretics are not recommended solely for potential beneficial effects in osteoporosis. Interest in the role of HMG-CoA reductase inhibitors (statins) in the treatment of osteoporosis came from boneforming properties seen in animal studies. However, controlled clinical trials are needed. Several studies have evaluated dietary supplements such as isoflavones, which are found in soy products and red clover. A well-controlled trial in more than 400 postmenopausal women evaluating a specific isoflavone, ipriflavone, found no benefits on bone mineral density or fracture rates after 3 years. Nevertheless, because these therapies are available without prescription and are not regulated by the FDA, patients may choose to self-medicate with isoflavones. Lymphocytopenia appeared in several patients treated with ipriflavone in clinical trials. Additionally, ipriflavone should be used with caution in immunocompromised patients or those with renal disease. It may inhibit CYP1A2 and CYP2C9 and may interact with drugs metabolized by those pathways, such as warfarin.

Results (Indonesian) 2:

8. Lain Terapi
Strontium ranelate adalah agen lisan memiliki sifat pembentuk tulang dan antiresorptive. Beberapa data menunjukkan penurunan yang signifikan pada patah tulang belakang. Namun, manfaat patah tulang nonvertebral tidak jelas. Agen ini belum disetujui untuk digunakan oleh FDA. Sodium fluoride merupakan agen dengan sifat pembentuk tulang. Penggunaannya telah jatuh dari nikmat setelah data menunjukkan peningkatan risiko fraktur meskipun terjadi peningkatan kepadatan mineral tulang. Saat ini tidak tersedia secara komersial di Amerika Serikat. Diuretik thiazide menurunkan ekskresi kalsium urin dan dapat menurunkan turnover tulang. Namun, efek mereka pada tingkat kepadatan mineral tulang dan fraktur belum diteliti dalam uji coba terkontrol. Diuretik thiazide tidak dianjurkan semata-mata untuk efek menguntungkan potensial dalam osteoporosis. Minat peran reduktase HMG-CoA (statin) dalam pengobatan osteoporosis datang dari boneforming properti terlihat pada hewan percobaan. Namun, uji klinis terkontrol diperlukan. Beberapa studi telah mengevaluasi suplemen makanan seperti isoflavon, yang ditemukan dalam produk kedelai dan semanggi merah. Sebuah uji coba terkontrol dengan baik di lebih dari 400 wanita pascamenopause mengevaluasi isoflavon tertentu, ipriflavone, tidak menemukan manfaat pada kepadatan atau fraktur tarif mineral tulang setelah 3 tahun. Namun demikian, karena terapi ini tersedia tanpa resep dan tidak diatur oleh FDA, pasien dapat memilih mengobati diri sendiri dengan isoflavon. Lymphocytopenia muncul di beberapa pasien yang diobati dengan ipriflavone dalam uji klinis. Selain itu, ipriflavone harus digunakan dengan hati-hati pada pasien immunocompromised atau mereka dengan penyakit ginjal. Ini dapat menghambat CYP1A2 dan CYP2C9 dan dapat berinteraksi dengan obat yang dimetabolisme oleh mereka jalur, seperti warfarin.